NOXXON Pharma

NOXXON Pharma AG is an independent biopharmaceutical company focusing on the development of innovative pharmaceutical products based on its unique proprietary Spiegelmer® Technology. The company is concentrating its attention on inflammatory diseases and haematological conditions. NOXXON's lead compound, NOX-E36 for treatment of kidney inflammation, is currently undergoing phase I clinical testing. A second Spiegelmer compound, NOX A12 for use in stem cell transplantation, is scheduled to enter phase I clinical testing later this year.

NOXXON's goal is the in-house development of our own Spiegelmer products through Phase II clinical trials. Complementing its own programs, NOXXON works on multiple drug discovery and development projects with its partners Eli Lilly, F. Hoffmann-La Roche, and Pfizer. The pursuit of licensing partnerships and collaborative Research & Development efforts is an integral part of our business strategy and plays an important role in the company's growth and success. This strategy reflects our strengths in drug discovery and the vast potential of our unique technology platform.
Type: NORMAL
Address: Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany
Website: www.noxxonpharma.com
Phone: + 49 30 726247-0
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.